Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III multicentre, randomized open-label study of Revlimid (lenalidomide) plus dexamethasone (ReDex) versus observation in patients with smoldering multiple myeloma (MM) at high risk of progression to symptomatic MM

Next Previous
X
Search
Trial Profile

A phase III multicentre, randomized open-label study of Revlimid (lenalidomide) plus dexamethasone (ReDex) versus observation in patients with smoldering multiple myeloma (MM) at high risk of progression to symptomatic MM

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Smoldering multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms QUIREDEX

    • Most Recent Events

    • 03 Sep 2022 Results of an analysis assessesd Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time published in the European Journal of Cancer
    • 21 Jun 2020 Results of 10 year follow up, presented at the 25th Congress of the European Haematology Association.
    • 26 Sep 2018 This trial has been discontinued in Spain.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top